Cancer Communications
indexed by SCI
BMC

Review
Post-translational modification of Parkin and its research progress in cancer
Dan Ding, Xiang Ao, Ying Liu, Yuan-Yong Wang, Hong-Ge Fa, Meng-Yu Wang, Yu-Qi He & Jian-Xun Wang
School of Basic Medical Sciences, Qingdao University, No. 38 Dengzhou Road, Shibei District, Qingdao, 266000, Shandong, P. R. China Center for Regenerative Medicine, Institute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266000, Shandong, P. R. China
[Abstract] Clinical practice has shown that Parkin is the major causative gene found in an autosomal recessive juvenile parkinsonism (AR-JP) via Parkin mutations and that the Parkin protein is the core expression product of the Parkin gene, which itself belongs to an E3 ubiquitin ligase. Since the discovery of the Parkin gene in the late 1990s, researchers in many countries have begun extensive research on this gene and found that in addition to AR-JP, the Parkin gene is associated with many diseases, including type 2 diabetes, leprosy, Alzheimer's, autism, and cancer. Recent studies have found that the loss or dysfunction of Parkin has a certain relationship with tumorigenesis. In general, the Parkin gene, a well-established tumor suppressor, is deficient and mutated in a variety of malignancies. Parkin overexpression inhibits tumor cell growth and promotes apoptosis. However, the functions of Parkin in tumorigenesis and its regulatory mechanisms are still not fully understood. This article describes the structure, functions, and post-translational modifications of Parkin, and summarizes the recent advances in the tumor suppressive function of Parkin and its underlying mechanisms.
Cancer Communications   Epub date: 11/21/2019   doi:10.1186/s40880-019-0421-5
[PDF Full-text]

[ Html full-text] (BioMed Central)

[ PubMed]

Cite this article

Dan Ding, Xiang Ao, Ying Liu, Yuan-Yong Wang, Hong-Ge Fa, Meng-Yu Wang, Yu-Qi He & Jian-Xun Wang. Post-translational modification of Parkin and its research progress in cancer. Cancer Commun (Lond). 2019, 39:77. doi:10.1186/s40880-019-0421-5


Export citations

EndNote

CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China